Seroatlas · Human Serome Atlas

CD69

Early activation antigen CD69

Also known as: CD69_HUMAN, CLEC2C

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q07108
Gene: CD69
Ensembl: ENSG00000110848
Chromosome: 12
Canonical length: 199 aa
Protein class: CD markers, Predicted membrane proteins
Quaternary structure: Homodimer

OverviewNCBI Gene

This gene encodes a member of the calcium dependent lectin superfamily of type II transmembrane receptors. Expression of the encoded protein is induced upon activation of T lymphocytes, and may play a role in proliferation. Furthermore, the protein may act to transmit signals in natural killer cells and platelets. [provided by RefSeq, Aug 2011]

Canonical amino-acid sequenceUniProt

199 residues, UniProt reviewed canonical sequence.

>Q07108|CD69
     1  MSSENCFVAE NSSLHPESGQ ENDATSPHFS TRHEGSFQVP VLCAVMNVVF ITILIIALIA
    61  LSVGQYNCPG QYTFSMPSDS HVSSCSEDWV GYQRKCYFIS TVKRSWTSAQ NACSEHGATL
   121  AVIDSEKDMN FLKRYAGREE HWVGLKKEPG HPWKWSNGKE FNNWFNVTGS DKCVFLKNTE
   181  VSSMECEKNL YWICNKPYK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CD69 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.43
Highest tissue expression: 160 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 160 nTPM
lymph node: 88 nTPM
tonsil: 56 nTPM
thymus: 53 nTPM
appendix: 45 nTPM
spleen: 42 nTPM

Single-cell type

mast cells: 3,282 nCPM
hematopoietic stem cells: 1,802 nCPM
innate lymphoid cells: 1,663 nCPM
t-cells: 1,522 nCPM
nk-cells: 1,211 nCPM
megakaryocyte-erythroid progenitors: 1,085 nCPM

Immune cell

MAIT T-cell: 31 nTPM
NK-cell: 27 nTPM
gdT-cell: 23 nTPM
naive CD4 T-cell: 21 nTPM
memory CD8 T-cell: 17 nTPM
naive CD8 T-cell: 16 nTPM

Brain region

white matter: 4.5 nTPM
spinal cord: 4 nTPM
choroid plexus: 3.9 nTPM
hypothalamus: 3 nTPM
medulla oblongata: 3 nTPM
pons: 2.2 nTPM

ReferencesPubMed · IEDB

Publications for CD69 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

6 publications

Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism.
2003 · Int J Immunopathol Pharmacol · RCR 2.5 · 89 citations
Autoantibodies to low-density-lipoprotein-receptor-related protein 2 (LRP2) in systemic autoimmune diseases.
2003 · Arthritis Res Ther · RCR 0.5 · 23 citations
Anti-CD69 autoantibodies cross-react with low density lipoprotein receptor-related protein 2 in systemic autoimmune diseases.
2001 · J Immunol · RCR 0.4 · 18 citations
Crosslinking of the CD69 molecule enhances S100A9 production in activated neutrophils.
2007 · Microbiol Immunol · RCR 0.3 · 13 citations
Encoding the Sequence of Specific Autoantibodies Against beta-Amyloid and alpha-Synuclein in Neurodegenerative Diseases.
2019 · Front Immunol · RCR 0.2 · 6 citations

Show 1 more

Autoantibodies to CD69 in patients with chronic hepatitis type C: a candidate marker for predicting the response to interferon therapy.
2003 · Intervirology · RCR 0.1 · 3 citations

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.92
gnomAD pLI: 0.03
gnomAD missense Z: -0.26
DepMap mean gene effect: 0.08
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of CD69 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CD69 as an antibody target. Whether an autoantibody or antibody against CD69 could matter depends on whether native CD69 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CD69 is annotated at the cell surface, where native CD69 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label CD69 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...